Skip to main content
. Author manuscript; available in PMC: 2010 Apr 16.
Published in final edited form as: J Neuroimmune Pharmacol. 2009 Mar 3;4(2):249–259. doi: 10.1007/s11481-009-9148-4

Fig. 6.

Fig. 6

Administration of O-1966 reduces CD11b and ICAM-1 expression during cerebral ischemic/reperfusion injury. Expression of CD11b and ICAM-1 was determined by immunohistochemistry on brain slices obtained 24 h after ischemia. Four treatment groups were compared: vehicle treated, O-1966 administered prior to MCAO, O-1966 administered 1 h after occlusion, and O-1966 administered 3 h after occlusion